42.50
+0.82(+1.97%)
Currency In USD
| Previous Close | 41.68 |
| Open | 41.81 |
| Day High | 42.77 |
| Day Low | 41.25 |
| 52-Week High | 62.53 |
| 52-Week Low | 24.1 |
| Volume | 5.34M |
| Average Volume | 1.29M |
| Market Cap | 4B |
| PE | -10.37 |
| EPS | -4.1 |
| Moving Average 50 Days | 33.1 |
| Moving Average 200 Days | 34.48 |
| Change | 0.82 |
If you invested $1000 in Crinetics Pharmaceuticals, Inc. (CRNX) since IPO date, it would be worth $1,733.99 as of October 08, 2025 at a share price of $42.5. Whereas If you bought $1000 worth of Crinetics Pharmaceuticals, Inc. (CRNX) shares 5 years ago, it would be worth $2,504.42 as of October 08, 2025 at a share price of $42.5.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
GlobeNewswire Inc.
Oct 06, 2025 8:05 PM GMT
SAN DIEGO, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025 after the market closes. Company management will host
Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly
GlobeNewswire Inc.
Sep 25, 2025 9:30 PM GMT
Palsonify Pills Palsonify pills Palsonify Logo Palsonify tablets Crinetics Exterior Crinetics headquarters in San Diego, CA Novel nonpeptide SST2 agonist PALSONIFY advances the treatment paradigm as the first once-daily, oral therapy app
Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Sep 10, 2025 8:30 PM GMT
SAN DIEGO, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on September 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an a